Coronary Artery Disease Therapeutics Market To Receive Overwhelming Hike In Revenues By 2026 With Top Players Astra Zeneca, Gilead, Novartis, Pfizer, Bayer, Merck & Co, Glaxo Smith Kline, and Mylan N.V

Coronary Artery Disease (CAD) is a medical condition developed due to damaged or diseased blood vessels, which supply blood, nutrients, and oxygen to the heart. Coronary heart disease is characterized by deposition of cholesterol plague in the arteries, which results into inflammation. Increasing deposition of plague eventually narrows the coronary arteries thereby decreasing the blood flow to the heart. Decrease of blood flow to the heart causes shortness of breath and chest pain leading to heart attack after complete blockage. Coronary artery disease is caused by smoking, high blood pressure, high cholesterol, diabetes or insulin resistance, sedentary lifestyle, and hypertension. Other factors involved in developing coronary artery disease include obesity, physical inactivity, high stress, and unhealthy diet.

Download PDF Brochure of This Business Report @ https://www.coherentmarketinsights.com/insight/request-pdf/1799

Coronary artery disease can be prevented by maintaining healthy diet, consumption of low fat and low salt fruits and vegetables, physical activity, and management of stress. Treatment of coronary artery disease includes cholesterol modifying medications, ACE inhibitors, Aspirin, beta blockers, Calcium channel blockers, and Ranolazine. Surgeries conducted to treat coronary artery disease include Nitroglycerin, Angioplasty, and coronary artery bypass surgery.

Coronary Artery Disease Therapeutics Market Drivers:-

The global market is expected to witness significant growth due to robust pipeline of drugs over the forecast period (2018-2026). For instance, hydroxychloroquine sulfate tablets sponsored by first affiliated hospital of Xi’an Jiaotong university, China is in the fourth phase of clinical trials, this drug suppresses symptoms of coronary artery disease. Atorvastatin sponsored by university health network, Toronto has completed phase two clinical trials in 2014, this drug reduces the risk of heart attack and myocardial infraction. PADMA 28 sponsored by University hospital Inselsiptal, Berne has completed phase 2 clinical trials in 2013, this drug has beneficial effect on arterial system, the autonomic nervous system and blood inflammatory markers in patients with coronary artery disease.

Furthermore, approval of new drugs for coronary artery disease is another factor driving growth of the coronary artery disease therapeutics market. For instance, in 2016, the U.S. FDA approved Yosprala (Aspirin and Omeprazole) by Aralez Pharmaceuticals, a Canada-based company, this drug is used to prevent cardiovascular diseases. In 2015, FDA approved Repatha by Amgen Inc. This drug is used to treat high cholesterol. In 2015, FDA approved Prestalia by Symplmed Pharmaceuticals LLC, this drug is used to treat hypertension for people suffering with heart disorders. Later in 2017, Prestalia was acquired by Marina Biotech Inc.

Competitive Analysis

Key players operating in coronary artery disease therapeutics market include Astra Zeneca, Gilead, Novartis, Pfizer, Bayer, Merck & Co, Glaxo Smith Kline, and Mylan N.V.

Talk To Our Analyst @ https://www.coherentmarketinsights.com/insight/talk-to-analyst/1799

Coronary Artery Disease Therapeutics Market Regional Analysis:-

North America is expected to hold dominant position in global coronary artery disease therapeutics market due to high prevalence of coronary artery disease. According to a survey conducted by Centers for disease control and prevention (CDC), in 2015, coronary heart disease kills more than 370,000 people annually in the U.S. out of which more than 92% had chest pain as a major symptom. According to a study conducted by American College of Cardiology, in 2017, more than 790000 people experience heart attack annually in the U.S. out of this around 47% people were reported to have hypertension and around 34% were reported to have high blood pressure.

Therefore, high prevalence of chronic diseases are expected to drive growth of this market over the forecast period. Asia Pacific coronary artery disease therapeutics market is projected to witness significant growth due to FDA approvals for generic drugs. For instance, in 2017, Lupin, India-based Company received FDA approval to launch generic version of Nadolol Tablets, indicated for the treatment of hypertension and angina pectoris.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.